ExpreS2ion’s platform (ExpreS2) featured in Viruses article on O-glycosylation on SARS-CoV-2 spike protein

ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) and its protein production platform ExpreS2™ have contributed to a scientific article published in the journal Viruses. The article describes the site-specific O-glycosylation analysis of SARS-CoV-2 spike protein produced in insect and human cells.

The scientific article is entitled “Site-Specific O-Glycosylation Analysis of SARS-CoV-2 Spike Protein Produced in Insect and Human Cells”.

Paper reference: Viruses 2021, 13(4), 551; https://doi.org/10.3390/v13040551, and can also be found at this link https://www.mdpi.com/1999-4915/13/4/551.

 

Certified Adviser

Svensk Kapitalmarknadsgranskning AB

Telephone: +46 11 32 30 732

E-mail: ca@skmg.se

 

For further information about ExpreS2ion, please contact:

Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail:
buf@expres2ionbio.com

About ExpreS2ion

ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion has developed a unique technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with leading research institutions and companies. Since 2017, ExpreS2ion develops novel VLP based vaccines through its joint venture AdaptVac ApS. For additional information, please visit www.expres2ionbio.com and www.adaptvac.com.

Tags: